
Opthea’s Phase 3 trial results fail to help patients, future of company at risk
Join our daily newsletter At The Bell to receive exclusive market insights It mightn’t be too surprising Opthea (ASX:OPT) applied for a voluntary suspension last week ahead of Monday’s Phase 3 trial results – they throw the future of the company into …